Latest News

This FAQ outlines key recommendations and practical takeaways from the 2026 AUA Medical Management of Kidney Stones guideline amendment.

Jonathan Harper, MD, discusses findings from the PUSH trial may inform counseling on hydration and stone recurrence.

A phase 1 study found topical sildenafil cream was linked with lower systemic exposure than oral sildenafil and was well tolerated in healthy men.

Cameron C. Jones, MD, discusses patient selection for Aquablation, including prostate size, anatomy, and factors that may favor alternative BPH procedures.

The study is assessing the safety and preliminary efficacy of CD28 co-stimulation in patients with mCRPC.

Andrew Peterson, MD, discusses the quality-of-life impact of post-cancer incontinence and advances in electronically controlled artificial urinary sphincters.

Eugene Cone, MD, discusses the impact of ongoing BCG supply challenges and the potential role of alternative and recombinant strains for NMIBC care.

Independent urology faces stagnant Medicare pay, rising costs, prior auth burden, and consolidation pressure, Celeste Kirschner, CAE, MHSA, says.

In this episode, Karen Bigman, MBA, joins to discuss sexual health, intimacy, and relationship challenges facing adults as they navigate midlife and beyond.

Urologists compare ADT plus ARPI doublets and docetaxel triplets in mCSPC, weighing efficacy, safety, cognition, and cost against patient goals.

All patients have been treated in the phase 3 ENLIGHTED trial, evaluating padeliporfin VTP for low-grade upper tract urothelial carcinoma.

Martin Schoen, MD, PhD, explains how real-world evidence can help compare ARPIs and why study design and patient selection are critical to interpretation.

John P. Sfakianos, MD, discusses the challenges of managing recurrent LG-IR-NMIBC and the role of chemoablation.